1 Mourkioti, F. & Rosenthal, N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med (Berl)86, 747-759, doi:10.1007/s00109-008-0308-4 (2008).
2 Zhang, G. et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat Commun8, 589, doi:10.1038/s41467-017-00726-x (2017).
3 Hadi, A. M. et al. Rapid quantification of myocardial fibrosis: A new macro-based automated analysis. Analytical cellular pathology33, 257-269, doi:10.3233/ACP-CLO-2010-0548 (2010).
4 Stephens, N. A., Skipworth, R. J. & Fearon, K. C. Cachexia, survival and the acute phase response. Curr Opin Support Palliat Care2, 267-274, doi:10.1097/SPC.0b013e3283186be2 (2008).
5 Hahn, A. et al. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. Journal of cachexia, sarcopenia and muscle11, 103-119, doi:10.1002/jcsm.12491 (2020).
6 Alhamarneh, O., Agada, F., Madden, L., Stafford, N. & Greenman, J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head & neck33, 415-423, doi:10.1002/hed.21464 (2011).
7 Ali, N. A. et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. American journal of respiratory and critical care medicine178, 261-268, doi:10.1164/rccm.200712-1829OC (2008).
8 Penet, M. F. & Bhujwalla, Z. M. Cancer cachexia, recent advances, and future directions. Cancer journal21, 117-122, doi:10.1097/PPO.0000000000000100 (2015).
9 Argiles, J. M., Busquets, S., Lopez-Soriano, F. J., Costelli, P. & Penna, F. Are there any benefits of exercise training in cancer cachexia? Journal of cachexia, sarcopenia and muscle3, 73-76, doi:10.1007/s13539-012-0067-5 (2012).
10 De Jonghe, B. et al. Paresis acquired in the intensive care unit: a prospective multicenter study. Jama288, 2859-2867, doi:10.1001/jama.288.22.2859 (2002).
11 Won, E. & Kim, Y. K. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int J Mol Sci18, doi:10.3390/ijms18122679 (2017).
12 Shorter, E. The history of lithium therapy. Bipolar Disord11 Suppl 2, 4-9, doi:10.1111/j.1399-5618.2009.00706.x (2009).
13 McKnight, R. F. et al. Lithium for acute mania. The Cochrane database of systematic reviews6, CD004048, doi:10.1002/14651858.CD004048.pub4 (2019).
14 Xu, M. et al. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3beta inhibitors: A critical review. Eur J Med Chem164, 448-470, doi:10.1016/j.ejmech.2018.12.073 (2019).
15 Hung, H. C., Shih, S. R., Chang, T. Y., Fang, M. Y. & Hsu, J. T. The combination effects of licl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication. PloS one9, e111331, doi:10.1371/journal.pone.0111331 (2014).
16 Thompson, C. L. et al. Lithium chloride prevents interleukin-1beta induced cartilage degradation and loss of mechanical properties. J Orthop Res33, 1552-1559, doi:10.1002/jor.22913 (2015).
17 Guttuso, T., Jr. High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced beta-catenin-mediated activity. Med Hypotheses131, 109302, doi:10.1016/j.mehy.2019.109302 (2019).
18 Verma, Y. K., Singh, A. K. & Gurudutta, G. U. Survival genes expression analysis following ionizing radiation to LiCl treated KG1a cells. Int J Radiat Biol, 1-18, doi:10.1080/09553002.2020.1721592 (2020).
19 Kim, A. R. et al. Screening ginseng saponins in progenitor cells identifies 20(R)-ginsenoside Rh2 as an enhancer of skeletal and cardiac muscle regeneration. Scientific reports10, 4967, doi:10.1038/s41598-020-61491-4 (2020).
20 Kim, Y. S. et al. Natural product derivative BIO promotes recovery after myocardial infarction via unique modulation of the cardiac microenvironment. Scientific reports6, 30726, doi:10.1038/srep30726 (2016).
21 Cho, H. et al. Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion. Clinical cancer research : an official journal of the American Association for Cancer Research, doi:10.1158/1078-0432.CCR-18-0125 (2018).
22 Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods65, 55-63 (1983).
23 Chen, X. et al. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Journal of cachexia, sarcopenia and muscle7, 225-232, doi:10.1002/jcsm.12054 (2016).
24 Jin, B. & Li, Y. P. Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. Journal of cellular biochemistry100, 960-969, doi:10.1002/jcb.21060 (2007).
25 Braun, T. P. et al. Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB journal : official publication of the Federation of American Societies for Experimental Biology27, 3572-3582, doi:10.1096/fj.13-230375 (2013).
26 Lee, J. H. et al. Inhibited inositol monophosphatase and decreased myo‐inositol concentration improve wasting in skeletal muscles. Clinical and translational medicine10, e251, doi:10.1002/ctm2.251 (2020).
27 Ma, Z., Zhong, Z., Zheng, Z., Shi, X. M. & Zhang, W. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced suppression of myogenic differentiation in vitro. PloS one9, e105528, doi:10.1371/journal.pone.0105528 (2014).
28 Abu-Baker, A. et al. Lithium chloride attenuates cell death in oculopharyngeal muscular dystrophy by perturbing Wnt/beta-catenin pathway. Cell death & disease4, e821, doi:10.1038/cddis.2013.342 (2013).
29 Kim, A., Im, M., Gu, M. J. & Ma, J. Y. Citrus unshiu peel extract alleviates cancer-induced weight loss in mice bearing CT-26 adenocarcinoma. Scientific reports6, 24214, doi:10.1038/srep24214 (2016).
30 Stambolic, V., Ruel, L. & Woodgett, J. R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Current biology : CB6, 1664-1668, doi:10.1016/s0960-9822(02)70790-2 (1996).
31 Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. & Goldberg, A. L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A98, 14440-14445, doi:10.1073/pnas.251541198 (2001).
32 Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell117, 399-412, doi:10.1016/s0092-8674(04)00400-3 (2004).
33 Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nat Commun4, 1332, doi:10.1038/ncomms2320 (2013).
34 Hung, Y. L. et al. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response. Scientific reports7, 46299, doi:10.1038/srep46299 (2017).
35 Kumar, S. et al. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. The American journal of pathology163, 2531-2541, doi:10.1016/s0002-9440(10)63608-5 (2003).
36 Narsale, A. A. & Carson, J. A. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care8, 321-327, doi:10.1097/SPC.0000000000000091 (2014).
37 Hall, D. T., Ma, J. F., Marco, S. D. & Gallouzi, I. E. Inducible nitric oxide synthase (iNOS) in muscle wasting syndrome, sarcopenia, and cachexia. Aging (Albany NY)3, 702-715, doi:10.18632/aging.100358 (2011).
38 Buck, M. & Chojkier, M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J15, 1753-1765 (1996).
39 Hall, D. T. et al. The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. EMBO molecular medicine10, doi:10.15252/emmm.201708307 (2018).
40 Tanaka, M., Miyazaki, H., Takeda, Y. & Takeo, S. Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. Cancer Lett72, 65-70, doi:10.1016/0304-3835(93)90012-x (1993).
41 Evans, W. J. et al. Cachexia: a new definition. Clin Nutr27, 793-799, doi:10.1016/j.clnu.2008.06.013 (2008).
42 Strassmann, G., Fong, M., Kenney, J. S. & Jacob, C. O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. The Journal of clinical investigation89, 1681-1684, doi:10.1172/JCI115767 (1992).
43 Strassmann, G. et al. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. The Journal of clinical investigation92, 2152-2159, doi:10.1172/JCI116816 (1993).
44 Schakman, O. et al. Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology149, 3900-3908, doi:10.1210/en.2008-0439 (2008).
45 Schmidt, M., Poser, C. & von Maltzahn, J. Wnt7a Counteracts Cancer Cachexia. Mol Ther Oncolytics16, 134-146, doi:10.1016/j.omto.2019.12.011 (2020).
46 Singh, N. et al. Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology41, 1768-1778, doi:10.1038/npp.2015.343 (2016).
47 Liu, L. et al. MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway. American journal of physiology. Cell physiology317, C189-C199, doi:10.1152/ajpcell.00419.2018 (2019).
48 Dehoux, M. et al. IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3beta pathways and inhibition of atrogin-1 mRNA. Am J Physiol Endocrinol Metab292, E145-150, doi:10.1152/ajpendo.00085.2006 (2007).
49 Verhees, K. J. et al. Glycogen synthase kinase-3beta is required for the induction of skeletal muscle atrophy. American journal of physiology. Cell physiology301, C995-C1007, doi:10.1152/ajpcell.00520.2010 (2011).
50 van der Velden, J. L. et al. Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. American journal of physiology. Cell physiology290, C453-462, doi:10.1152/ajpcell.00068.2005 (2006).
51 Ragozzino, E. et al. 6-Bromoindirubin-3'-oxime intercepts GSK3 signaling to promote and enhance skeletal muscle differentiation affecting miR-206 expression in mice. Scientific reports9, 18091, doi:10.1038/s41598-019-54574-4 (2019).
52 Liu, L. et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer research71, 3972-3979, doi:10.1158/0008-5472.CAN-10-3852 (2011).
53 Guadagnin, E., Mazala, D. & Chen, Y. W. STAT3 in Skeletal Muscle Function and Disorders. Int J Mol Sci19, doi:10.3390/ijms19082265 (2018).
54 Qin, L. et al. A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics11, 320, doi:10.1186/1471-2164-11-320 (2010).
55 Eldar-Finkelman, H., Schreyer, S. A., Shinohara, M. M., LeBoeuf, R. C. & Krebs, E. G. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes48, 1662-1666, doi:10.2337/diabetes.48.8.1662 (1999).
56 Tomasin, R., Martin, A. & Cominetti, M. R. Metastasis and cachexia: alongside in clinics, but not so in animal models. Journal of cachexia, sarcopenia and muscle10, 1183-1194, doi:10.1002/jcsm.12475 (2019).
57 PV, S. et al. Effect of lithium administration on muscle and body weight loss in experimental cancer cachexia. European Journal of Internal Medicine19S, S1–S59 (2008).
58 Bertsch, S., Lang, C. H. & Vary, T. C. Inhibition of glycogen synthase kinase 3[beta] activity with lithium in vitro attenuates sepsis-induced changes in muscle protein turnover. Shock35, 266-274, doi:10.1097/SHK.0b013e3181fd068c (2011).
59 Khasraw, M., Ashley, D., Wheeler, G. & Berk, M. Using lithium as a neuroprotective agent in patients with cancer. BMC Med10, 131, doi:10.1186/1741-7015-10-131 (2012).
60 van der Werf, A., van Bokhorst, Q. N. E., de van der Schueren, M. A. E., Verheul, H. M. W. & Langius, J. A. E. Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer. Nutr Cancer70, 1322-1329, doi:10.1080/01635581.2018.1504092 (2018).
61 Argiles, J. M., Lopez-Soriano, F. J., Stemmler, B. & Busquets, S. Therapeutic strategies against cancer cachexia. Eur J Transl Myol29, 7960, doi:10.4081/ejtm.2019.7960 (2019).
62 Alsady, M., Baumgarten, R., Deen, P. M. & de Groot, T. Lithium in the Kidney: Friend and Foe? Journal of the American Society of Nephrology : JASN27, 1587-1595, doi:10.1681/ASN.2015080907 (2016).
63 Martinsson, L., Westman, J., Hallgren, J., Osby, U. & Backlund, L. Lithium treatment and cancer incidence in bipolar disorder. Bipolar Disord18, 33-40, doi:10.1111/bdi.12361 (2016).
64 Zarse, K. et al. Low-dose lithium uptake promotes longevity in humans and metazoans. Eur J Nutr50, 387-389, doi:10.1007/s00394-011-0171-x (2011).